British pharmaceutical giant GSK has announced its first share buyback programme in over a decade, committing £2 billion to the initiative whilst simultaneously upgrading its long-term sales projections. The FTSE
Pharmaceutical9- Page
192Articles
British pharmaceutical giant AstraZeneca has abandoned its £450 million expansion plans for its vaccine manufacturing facility in Speke, Liverpool, delivering a significant blow to the UK’s life sciences sector. The
Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable listed company, has received a stern reprimand from the Prescription Medicines Code of Practice Authority (PMCPA) for systematically failing to disclose healthcare
The surging popularity of weight-loss medications is creating unprecedented ripples across the alcohol industry, with major beverage companies facing potential long-term revenue challenges. Investment heavyweight Terry Smith’s recent divestment from
The Sackler family and their pharmaceutical enterprise Purdue Pharma have reached a landmark £7.4 billion settlement over their involvement in the US opioid crisis, marking a significant development in one
In a groundbreaking announcement at the World Economic Forum in Davos, Sir Demis Hassabis revealed that Isomorphic Labs, the Alphabet-owned drug discovery startup, will commence trials of its first AI-designed
A critical £450 million investment by pharmaceutical giant AstraZeneca in a new vaccines facility in Speke, Liverpool, has encountered significant delays due to prolonged government deliberations on support measures. The
Weight Loss Drugs Show Promise in Reducing Alzheimers Risk and Other Health Conditions Study Reveals
A groundbreaking study involving 215,000 US military veterans with diabetes has revealed that popular weight-loss medications demonstrate a 12 per cent reduction in Alzheimer’s disease risk, whilst simultaneously highlighting increased
A groundbreaking clinical trial at University College London (UCL) is poising to transform the landscape of alcohol misuse treatment through the utilisation of dimethyltryptamine (DMT), a potent psychedelic compound. The
British pharmaceutical giant GSK has struck a significant deal worth up to $1.15 billion to acquire IDRx, a Massachusetts-based biopharmaceutical company, strengthening its position in the oncology sector. The FTSE
In a significant move that marks the largest biotech acquisition since 2023, Johnson & Johnson has announced its agreement to purchase neuroscience drugmaker Intra-Cellular Therapies for £14.6 billion. The New
In a devastating blow to investor confidence, Moderna’s shares experienced a dramatic decline of up to 22 per cent on Monday following disappointing sales forecasts from the US biotech giant.
Liverpool’s burgeoning life sciences sector is positioning itself as one of Europe’s premier biotech clusters, with projections indicating up to £800 million in investment over the next decade. The region’s
The struggling consumer healthcare company Alliance Pharma appears poised to exit London’s junior stock exchange following a £350 million takeover bid from activist investor Dbay Advisors. The Isle of Man-based
A groundbreaking series A funding round has positioned London-based Verdiva Bio at the forefront of the obesity treatment sector, securing an impressive $411 million investment. This remarkable achievement stands as
A landmark research initiative analysing blood proteins could catalyse significant advancements in disease treatment and prevention, presenting substantial opportunities for healthcare sector investors. The extensive UK-based study, backed by 14
